CTLA4 and neoplasm: Negative regulators of the immune response cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and the programed death receptor 1 (PD-1), as well as its ligands, programmed death ligands 1 and 2 (PD-L1 and PD-L2), became main targets of tumor immunotherapies [14].